XOMA Royalty FY2026 EPS Forecast Boosted by HC Wainwright

Key Points

• HC Wainwright has raised its FY2026 earnings per share estimate for XOMA Royalty from $1.16 to $1.34, maintaining a "Buy" rating and setting a price target of $104.00.
• XOMA Royalty recently reported earnings of $0.48 per share for the last quarter, surpassing estimates of a loss of ($0.12) by $0.60 and generating $13.13 million in revenue.
• Several analysts, including Zacks Research and Wall Street Zen, have upgraded XOMA Royalty's stock rating, contributing to a current consensus rating of "Moderate Buy" with an average target price of $69.50.

XOMA Royalty Corporation (NASDAQ:XOMA - Free Report) - Investment analysts at HC Wainwright boosted their FY2026 earnings estimates for shares of XOMA Royalty in a research note issued to investors on Thursday, August 21st. HC Wainwright analyst J. Pantginis now anticipates that the biotechnology company will post earnings per share of $1.34 for the year, up from their previous forecast of $1.16. HC Wainwright currently has a "Buy" rating and a $104.00 price target on the stock. The consensus estimate for XOMA Royalty's current full-year earnings is ($1.41) per share.

Several other equities analysts also recently weighed in on XOMA. Zacks Research raised XOMA Royalty to a "hold" rating in a research report on Tuesday, August 12th. Wall Street Zen raised XOMA Royalty from a "hold" rating to a "buy" rating in a research report on Monday, August 11th. Two research analysts have rated the stock with a Buy rating and one has given a Hold rating to the company. According to data from MarketBeat, the company currently has a consensus rating of "Moderate Buy" and a consensus price target of $69.50.

XOMA Royalty Trading Down 1.0%

Shares of NASDAQ:XOMA traded down $0.34 during midday trading on Friday, reaching $33.86. 9,151 shares of the company's stock were exchanged, compared to its average volume of 44,743. The firm's 50 day simple moving average is $27.59 and its two-hundred day simple moving average is $24.68. The company has a debt-to-equity ratio of 1.41, a current ratio of 4.88 and a quick ratio of 4.88. The stock has a market cap of $409.24 million, a price-to-earnings ratio of -21.84 and a beta of 1.00. XOMA Royalty has a fifty-two week low of $18.35 and a fifty-two week high of $35.22.

XOMA Royalty (NASDAQ:XOMA - Get Free Report) last released its quarterly earnings results on Wednesday, August 13th. The biotechnology company reported $0.48 earnings per share (EPS) for the quarter, beating analysts' consensus estimates of ($0.12) by $0.60. The firm had revenue of $13.13 million for the quarter, compared to analysts' expectations of $9.39 million. XOMA Royalty had a negative net margin of 27.57% and a positive return on equity of 2.63%.

Institutional Investors Weigh In On XOMA Royalty

A number of institutional investors and hedge funds have recently added to or reduced their stakes in the company. Opaleye Management Inc. lifted its stake in XOMA Royalty by 0.8% in the second quarter. Opaleye Management Inc. now owns 255,087 shares of the biotechnology company's stock valued at $6,428,000 after buying an additional 2,044 shares during the last quarter. Geode Capital Management LLC raised its stake in shares of XOMA Royalty by 9.1% during the second quarter. Geode Capital Management LLC now owns 203,601 shares of the biotechnology company's stock worth $5,132,000 after purchasing an additional 16,929 shares during the last quarter. Woodline Partners LP raised its stake in shares of XOMA Royalty by 7.9% during the first quarter. Woodline Partners LP now owns 168,550 shares of the biotechnology company's stock worth $3,359,000 after purchasing an additional 12,284 shares during the last quarter. Stonepine Capital Management LLC raised its stake in shares of XOMA Royalty by 17.2% during the second quarter. Stonepine Capital Management LLC now owns 152,143 shares of the biotechnology company's stock worth $3,834,000 after purchasing an additional 22,330 shares during the last quarter. Finally, Northern Trust Corp raised its position in XOMA Royalty by 1.5% in the fourth quarter. Northern Trust Corp now owns 91,181 shares of the biotechnology company's stock worth $2,396,000 after acquiring an additional 1,340 shares in the last quarter. Hedge funds and other institutional investors own 95.92% of the company's stock.

About XOMA Royalty

XOMA Corporation operates as a biotech royalty aggregator in the United States and the Asia Pacific. It has a portfolio of economic rights to future potential milestone and royalty payments associated with partnered commercial and pre-commercial therapeutic candidates. The company also focuses on early to mid-stage clinical assets primarily in Phase 1 and 2 with commercial sales potential that are licensed to partners; and acquires milestone and royalty revenue streams on late-stage clinical or commercial assets.